We investigated the impact of the MAPK family inhibitors Selumetinib (MEK1 and MEK2) and JNK-IN-8 (JNK family), and the impact of CDK family kinase inhibitors Roscovitine (CDK2, CDK5), Dinaciclib (CDK4, CDK6), and the non-specific CDK/Crk during infection (Fig. EV2A,B). Here, MAP2K2 is linked to infection.